Cipla is currently trading at Rs. 575.15, up by 1.15 points or 0.20% from its previous closing of Rs. 574.00 on the BSE.
The scrip opened at Rs. 571.00 and has touched a high and low of Rs. 577.35 and Rs. 563.80 respectively. So far 33139 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 562.80 on 02-Feb-2016.
Last one week high and low of the scrip stood at Rs. 606.35 and Rs. 562.80 respectively. The current market cap of the company is Rs. 45680.90 crore.
The promoters holding in the company stood at 37.57% while Institutions and Non-Institutions held 35.53% and 26.89% respectively.
In a move aimed at realignment of family shareholding, Cipla patriarch Y K Hamied, Non-Executive Chairman of the company has acquired 5.22% additional stake in the company from his wife Farida Hamied. Following the acquisition, his total holding in the drug firm increased to 20.76% from earlier stake of 15.54%.
The transfer of shares is being done by way of gift. The development comes at a time when the Mumbai-based drug maker is in the midst of a transition in leadership.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.15 |
| Dr. Reddys Lab | 1236.65 |
| Cipla | 1236.45 |
| Zydus Lifesciences | 938.75 |
| Lupin | 2328.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: